公开(公告)号：US20220298222A1

公开(公告)日：2022-09-22

申请号：US17636181

申请日：2020-08-21

申请人： Juno Therapeutics, Inc.

发明人： Henry CHANG ,  Ellen FILVAROFF ,  Brian FOX ,  Adithi MOHAN ,  Katie NEWHALL ,  Nels Eric OLSON

IPC分类号： C07K14/725 ,  A61P35/00

摘要： Provided are methods, uses, and articles of manufacture of combination therapies involving immunotherapies and cell therapies, such as adoptive cell therapy, e.g. a T cell therapy, and the use of an inhibitor of an enhancer of zeste homolog 2 (EZH2), for treating subjects having or suspected of having a cancer, and related methods, uses, and articles of manufacture. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs).

公开(公告)号：US20220096651A1

公开(公告)日：2022-03-31

申请号：US17421365

申请日：2020-01-28

申请人： Juno Therapeutics, Inc.

发明人： Andreia COSTA ,  Rupesh AMIN ,  Jenna BAILEY ,  Samriti BEDI ,  Brian BELMONT ,  Aye CHEN ,  Stephen Jacob GOLDFLESS ,  Eric JEFFERY ,  Yue JIANG ,  Yeonjoo OH ,  Madeline WILLIAMS ,  Collin HAUSKINS ,  Catherine SIERRA

IPC分类号： A61K47/68 ,  A61P35/00 ,  A61K35/17 ,  C12N5/10 ,  C12N15/63 ,  C12N15/62

摘要： Provided are receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, in particular, to human antibodies specific for ROR1, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for ROR1. The disclosure further relates to genetically engineered cells, containing such ROR1-binding proteins and receptors, and related methods and uses thereof in adoptive cell therapy.

公开(公告)号：US20220009992A1

公开(公告)日：2022-01-13

申请号：US17291985

申请日：2019-11-08

申请人： FRED HUTCHINSON CANCER RESEARCH CENTER ,  JUNO THERAPEUTICS, INC.

发明人： Thomas M. SCHMITT ,  Aude G. CHAPUIS ,  Philip D. GREENBERG

IPC分类号： C07K14/725 ,  C12N15/86 ,  A61K35/17 ,  A61K45/06 ,  A61P35/00

摘要： Binding proteins specific for Msln20-28 or Msln530-538 peptides are provided herein. Polynucleotides encoding the binding proteins, as well as compositions and recombinant host cells comprising the binding proteins or polynucleotides are also provided. The compositions and recombinant host cells may be used to treat a subject having mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, a cancer wherein an Msln20-28 peptide is expressed on a tumor cell of the cancer, or a cancer wherein an Msln530-538 peptide is expressed on a tumor cell of the cancer.

公开(公告)号：US20210255173A1

公开(公告)日：2021-08-19

申请号：US16604547

申请日：2018-04-13

申请人： Juno Therapeutics, Inc.

发明人： Paul Ken KODAMA ,  Tom KOWSKI ,  Mirna MUJACIC ,  Kenneth Mayo PRENTICE

IPC分类号： G01N33/53 ,  C12Q1/34 ,  G01N33/50

摘要： Provided herein are methods for assessing cell surface glycans, e.g., N-glycans, by assessing a sample of released surface glycans, and determining the presence, absence, or level of glycans present in the sample. Also provided are methods of assaying and/or evaluating a cell composition by assessing the cell surface glycan profile of the cell composition and comparing the profile to a reference sample. Methods for manufacturing and/or culturing a plurality of cell compositions having consistent surface glycan expression with low variability are also provided.

公开(公告)号：US11072660B2

公开(公告)日：2021-07-27

申请号：US16338452

申请日：2017-10-03

申请人： Juno Therapeutics, Inc.

发明人： James Sissons ,  Cameron Brandt ,  Alexandra Croft ,  Allen Ebens ,  Haley Peper ,  Dean Y. Toy

IPC分类号： C07K14/705 ,  C07K16/28 ,  C07K14/725 ,  C07K16/08 ,  A61P31/20 ,  A61K39/12 ,  A61K39/00

摘要： Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.

公开(公告)号：US20210207080A1

公开(公告)日：2021-07-08

申请号：US16770052

申请日：2018-12-07

申请人： Juno Therapeutics, Inc.

发明人： Pascal BEAUCHESNE ,  Kien KHUU-DUONG ,  Ivie AIFUWA ,  Calvin CHAN

IPC分类号： C12N5/00 ,  C12N5/0783

摘要： Provided herein is a serum-free media for culturing, such as cultivating, preparing and/or producing cells, such as immune cells, such as genetically engineered cells. Also provided is a liquid basal media and frozen supplements that can be used to produce serum-free media. The provided embodiments include methods for producing serum-free media and methods for culturing cells, such as activating, transducing, cultivating or expanded cells, in the presence of serum-free media.

公开(公告)号：US11020429B2

公开(公告)日：2021-06-01

申请号：US15773153

申请日：2016-11-04

申请人： Juno Therapeutics, Inc.

发明人： Lucas James Thompson

IPC分类号： A61K35/17 ,  A61K39/00 ,  C12N5/0783

摘要： Provided are cells, e.g., engineered immune cells, expressing recombinant or engineered molecules involved in metabolic pathways, such as those that promote or inhibit one or more metabolic steps, reactions, or pathways, for example, in T cells. Such molecules include those that induce or repress a particular functional outcome or metabolic event, for example, one that promotes differentiation or reprogramming into a particular phenotypic state, such as memory, long-lived, activated or activatable, non-exhausted, phenotype or stem-like phenotype. The cells generally further express an immune receptor, such as an antigen receptor, which may be an engineered receptor, such as a CAR or recombinant TCR, or may be a natural immune receptor. Also provided are cells, such as T cells, expressing such molecules and combinations thereof, compositions comprising such cells, nucleic acids such as vectors encoding the same, and methods of administration to subjects in adoptive cell therapy.

公开(公告)号：US10786533B2

公开(公告)日：2020-09-29

申请号：US15744744

申请日：2016-07-15

申请人： Juno Therapeutics, Inc.

发明人： Kendall M. Mohler ,  Hyam I. Levitsky ,  Blythe Sather

IPC分类号： A01N63/00 ,  C12N5/071 ,  C07H21/02 ,  C07K14/00 ,  A61K35/17 ,  C12N5/0783 ,  C12N15/86 ,  C07K14/435 ,  C12N5/078

摘要： Provided are engineered cells for adoptive therapy, including NK cells and T cells. Also provided are compositions for engineering and producing the cells, compositions containing the cells, and methods for their administration to subjects. In some embodiments, the cells contain genetically engineered antigen receptors that specifically bind to antigens, such as chimeric antigen receptors (CARs) and costimulatory receptors. In some embodiments, the cells include receptors targeting multiple antigens. In some embodiments, the cells include repression of one or more gene product, for example, by disruption of a gene encoding the gene product. In some embodiments, a gene encoding an antigen recognized by the engineered antigen receptor is disrupted, reducing the likelihood of targeting of the engineered cells. In some embodiments, the antigen recognized by the engineered antigen receptor is related to a tumor antigen recognized by the engineered antigen receptor.

公开(公告)号：US20200054680A1

公开(公告)日：2020-02-20

申请号：US16667564

申请日：2019-10-29

申请人： Juno Therapeutics, Inc.

发明人： Mark J. GILBERT

IPC分类号： A61K35/17 ,  B65D25/20 ,  A61K45/06 ,  C07K16/28

摘要： Provided are methods for administering multiple doses of cells, such as T cells, to subjects for cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods generally involve administering a first and at least one consecutive dose of the cells. Timing of the doses relative to one another, and/or size of the doses, in some embodiments provide various advantages such as lower or reduced toxicity and improved efficacy, for example, due to increased exposure of the subject to the administered cells. In some embodiments, the first dose is a relatively low dose, such as one that reduces tumor or disease burden, thereby improving the efficacy of consecutive or subsequent doses, and the consecutive dose is a consolidating dose.

公开(公告)号：US20200054673A1

公开(公告)日：2020-02-20

申请号：US16340085

申请日：2017-10-13

申请人： JUNO THERAPEUTICS, INC.

发明人： Michael PORTS ,  Evan Paul THOMAS ,  Hyam I. LEVITSKY

IPC分类号： A61K35/17 ,  A61K31/4245 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/90 ,  G01N33/574

摘要： Provided are methods of treatment involving immunotherapy, such as T cell therapy, and administration of a tryptophan metabolism and/or kynurenine pathway modulator. In some embodiments, the method includes a combination therapy that involves administration of engineered T cells, such as chimeric antigen receptor (CAR)-expressing cells, and a tryptophan metabolism and/or kynurenine pathway modulator, such as an inhibitor of an enzyme. Also provided are engineered cells in which the expression of a molecule involved in the kynurenine pathway is modified. Also provided are methods of manufacturing engineered cells, cells, compositions, methods of administration to subjects, nucleic acids and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, activity, outcome, function, response, persistence, expansion and/or proliferation of cells for adoptive cell therapy.